NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action
April 14, 2023 08:00 ET
|
NuCana plc
NUC-7738 Reduces Secreted Forms of PD-L1 Indicating Potential Synergy with Checkpoint Inhibitors NUC-7738 Decreases Glutaminase in vitro and in Cancer Tissue Demonstrating Potential for Anti-Cancer...
NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
April 04, 2023 16:01 ET
|
NuCana plc
Multiple Important Data Readouts Expected in 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, April 04, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA)...
Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana’s ‘190 Patent is Not Valid
March 24, 2023 16:30 ET
|
NuCana plc
MUNICH, Germany, March 24, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a hearing on March 24, 2023, the Technical Board of Appeal (the “TBA”) of the European Patent...
NuCana to Participate in Two Upcoming Investor Conferences
February 28, 2023 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 23, 2023 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Jan. 23, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”)...
NuCana Announces Receipt of NASDAQ Notice
January 06, 2023 16:01 ET
|
NuCana plc
EDINBURGH, United Kingdom, Jan. 06, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that it received written notification (the “Notification Letter”) from The Nasdaq Stock Market...
NuCana to Host Investor Meetings During the J.P. Morgan Healthcare Conference
January 03, 2023 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Jan. 03, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that management will host one-on-one meetings during the 41st Annual J.P. Morgan Healthcare...
NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update
November 16, 2022 16:01 ET
|
NuCana plc
Multiple Data Readouts on Track for the Remainder of 2022 and the First Half of 2023 Well Capitalized with Anticipated Cash Runway into 2025 EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE...
NuCana to Present at the Jefferies London Healthcare Conference
November 08, 2022 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022
October 26, 2022 07:00 ET
|
NuCana plc
NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in Combination...